225 related articles for article (PubMed ID: 17881400)
1. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.
Haas J; Hommes OR
Mult Scler; 2007 Aug; 13(7):900-8. PubMed ID: 17881400
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
4. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.
Achiron A; Kishner I; Dolev M; Stern Y; Dulitzky M; Schiff E; Achiron R
J Neurol; 2004 Sep; 251(9):1133-7. PubMed ID: 15372259
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Khan OA; Tselis A; Boster A
Neurology; 2009 Jun; 72(24):2134; author reply 2134-5. PubMed ID: 19528523
[No Abstract] [Full Text] [Related]
9. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.
Bayry J; Hartung HP; Kaveri SV
Trends Pharmacol Sci; 2015 Jul; 36(7):419-21. PubMed ID: 26003802
[TBL] [Abstract][Full Text] [Related]
10. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis.
Brandt-Wouters E; Gerlach OH; Hupperts RM
Int J Gynaecol Obstet; 2016 Aug; 134(2):194-6. PubMed ID: 27177509
[TBL] [Abstract][Full Text] [Related]
11. The Austrian Immunoglobulin in MS (AIMS) study: final analysis.
Strasser-Fuchs S; Fazekas F; Deisenhammer F; Nahler G; Mamoli B
Mult Scler; 2000 Oct; 6 Suppl 2():S9-13. PubMed ID: 11188778
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis and reproductive risks in women.
Argyriou AA; Makris N
Reprod Sci; 2008 Oct; 15(8):755-64. PubMed ID: 19017813
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.
Dudesek A; Zettl UK
J Neurol; 2006 Sep; 253 Suppl 5():V50-8. PubMed ID: 16998754
[TBL] [Abstract][Full Text] [Related]
14. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
15. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
Sørensen PS
Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
[TBL] [Abstract][Full Text] [Related]
17. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
Johnson KP; Ford CC; Lisak RP; Wolinsky JS
Acta Neurol Scand; 2005 Jan; 111(1):42-7. PubMed ID: 15595937
[TBL] [Abstract][Full Text] [Related]
18. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period.
Winkelmann A; Rommer PS; Hecker M; Zettl UK
CNS Neurosci Ther; 2019 Jan; 25(1):78-85. PubMed ID: 29858532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
